Business Context and Reporting Period
This Form 8-K is a current report filed by Ventrus Biosciences, Inc. (noted as Assembly Biosciences, Inc. in metadata) on May 31, 2011. The filing addresses a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The material event reported is the U.S. Patent and Trademark Office (USPTO) finding the company's pending U.S. Patent Application No. 09/355,928 patentable. A Notice of Allowance was posted on May 26, 2011. The patent is titled "TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING A CHOLINERGIC AGENT OR A CALCIUM CHANNEL BLOCKER."
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or a discussion of risks and contingencies. The document serves solely to disclose the patent allowance and incorporates a press release as Exhibit 99.1.
Investor Verification Checklist
- Verify the final issuance date and number of the patent following the Notice of Allowance.
- Confirm the commercial viability and development status of the topical pharmaceutical composition covered by the patent.
- Review the attached press release (Exhibit 99.1) for additional details on the patent's scope and potential market impact.